Umbrella, Basket, and Platform Trials: What the FDA's Master-Protocol Guidance Actually Changes

The FDA's revised draft guidance on master protocols, published in the Federal Register on June 24, 2026, does not invent umbrella, basket, and platform trials. It clarifies how a single overarching protocol can study several drugs or several diseases at once, adds a dedicated section on basket trials in response to public comments, and sharpens what the agency expects around shared controls, randomization, choice of comparator, and multiplicity. The document revises and replaces the December 22, 2023 draft, and comments are open through August 24, 2026.

What a master protocol is

A master protocol is one governing framework under which multiple substudies run, sharing infrastructure such as eligibility screening, a data-management system, and often a common control group. The appeal is efficiency: instead of standing up a separate trial for every drug-disease pairing, investigators leverage shared machinery and, sometimes, shared data across related conditions. The FDA's guidance groups these designs into three families and describes recommendations for their design, analysis, and regulatory submission.

The three labels get used loosely in press coverage, so precise definitions matter. A useful reference point is the 2019 systematic review by Park and colleagues in Trials, which cataloged how these designs are actually built and reported.

Umbrella trials

An umbrella trial studies multiple investigational therapies within a single disease, usually assigning patients to arms based on a biomarker or other patient characteristic. Park and colleagues framed umbrella designs as stratifying one disease into subgroups defined by molecular alterations or other features, then testing a targeted intervention within each. Oncology has driven most of this work, where a single tumor type is partitioned by mutation and each subgroup receives a matched agent.

Basket trials

A basket trial inverts that logic: one investigational therapy across multiple diseases or disease subtypes that share a common predictive biomarker or characteristic. The classic motivation is a drug targeting a specific molecular alteration that appears across otherwise unrelated cancers. The revised guidance devotes new attention here precisely because sponsors asked for it. The added recommendations address how to evaluate a drug's effect when the same agent is studied across heterogeneous populations, offering approaches that range from a combined analysis pooling across substudies to separate analyses within each individual basket.

Platform trials

A platform trial uses an adaptive structure that lets treatment arms enter or leave over time as evidence accumulates, rather than fixing every arm at the outset. Park and colleagues described these as trials allowing intervention arms to be dropped and new ones introduced during the study, overlapping with multi-arm, multi-stage designs. Trials such as I-SPY 2 in breast cancer, STAMPEDE in prostate cancer, and RECOVERY during the pandemic are widely cited examples of this perpetual, evolving structure.

What the revision actually changes

The headline is narrower than some coverage implies. The FDA states that the changes from the original draft are more detailed recommendations on basket trials plus minor clarifications on topics including randomization, choice of control, and informed consent. This is a refinement, not a reinvention. The core message, that a master protocol can improve efficiency by leveraging a shared control arm when evaluating multiple drugs and by borrowing information across related conditions, carries over from the earlier draft.

Two appraisal tradeoffs deserve emphasis, because they are where efficiency and rigor pull against each other.

Shared controls

A shared control arm is the central efficiency lever. If several experimental arms are each compared against one common control group, fewer patients are randomized to placebo or standard care overall, and the trial runs faster. The cost is that any comparison now depends on a control group that may have been recruited at a different time or under slightly different conditions than a given experimental arm. Concurrent randomization, where each experimental arm is compared only against controls enrolled during the same window, protects against drift in patient mix and standard of care over a long-running platform. When comparisons lean on non-concurrent controls, the interpretive burden rises, and that is a fair question to ask of any master-protocol result.

Multiplicity

Testing many arms or many populations under one protocol multiplies the number of statistical comparisons, and every added comparison inflates the chance of a false-positive somewhere in the family of tests. The guidance flags multiplicity as a design consideration that sponsors must plan for rather than patch afterward. For readers appraising a published master-protocol trial, the practical questions are whether the analysis was pre-specified, whether Type I error was controlled across substudies or only within them, and whether a pooled claim across baskets rests on genuine homogeneity of effect or papers over real differences between diseases. A drug can look effective in a combined basket analysis while working in only one or two of the constituent conditions, which is why the choice between pooled and substudy-level analysis is not a technicality.

This is educational content and not medical advice; treatment decisions belong to an individual and their treating clinician.

How to read the guidance

Draft guidance describes the FDA's current thinking; it is not a regulation and does not bind sponsors or the agency, and the August 24, 2026 comment window means the text may still shift. Read as a neutral map, the document is best understood as codifying expectations that good trialists already hold: name the design honestly, justify the control structure, pre-specify the analysis, and account for every comparison being made. The efficiency of master protocols is real, and so is the added interpretive care their results demand. Both can be true at once, and the guidance is largely an effort to keep them in balance.